Over 250,000 new cases of head and neck cancers (HNCs) and non-small cell lung cancers (NSCLCs) are diagnosed every year in the United States. At the time of diagnosis, 60% of these cases are regionally advanced (stage III and IV). Wide surgical excision is not the immediate therapeutic option for most of these locally advanced solid tumor malignancies. A number of studies have shown that a course of combined chemotherapy and radiotherapy, also known as chemoradiotherapy (CRT), promises superior results over chemotherapy or radiation therapy alone. The ability of radiation to eradicate cancer cells depends critically upon the presence of molecular oxygen, a potent radiosensitizer involved in mediating DNA damage. While low oxygen levels (hypoxia) has been recognized as a cause of treatment failure in solid tumors for more than 50 years, previous attempts to improve tumor oxygenation, including whole-body hyperbaric oxygen and systemic erythropoietin treatments, have had limited success. Vindico NanoBioTechnology, Inc. (Vindico), proposes to develop a novel nanoparticle-based therapeutic adjuvant that improves radiation and chemotherapy of HNCs, NSCLCs, as well as other solid tumor malignancies. The goal of this Phase I SBIR project is to create nanoparticle composites that exhibit the requisite in situ properties for safe and effective in vivo oxygen delivery. In colaboration with researchers from Duke University, these agents will be tested for their ability to modulate in vivo tumor oxygenation. Subsequent Phase II work will generate crucial pre-clinical animal data regarding toxicity and the ability of these novel nanoparticles to augment radiotherapy.
Public Health Relevance: The proposed project aims to utilize nanotechnology to deliver a natural protein that increases tumor oxygen levels. This research will have a major impact on public health by resulting in a novel agent that improves cancer radiation and chemotherapy. The end result wil be increased patient survival and an enhanced standard of care. Significant additional advantages include tremendous cost savings to the health care system, in reduced operating and therapeutic costs, as well as local job creation and economic stimulus.
Thesaurus Terms: Abscission;Acute;Adjuvant;Aerobic;Affect;B Element;Binding;Binding (Molecular Function);Biodegradation;Blood Circulation Time;Body Tissues;Boron;Bp50;Cd40;Cdw40;Caliber;Cancers;Cell Growth In Number;Cell Multiplication;Cell Proliferation;Cellular Proliferation;Characteristics;Chemistry;Collaborations;Cost Savings;Creatinine Clearance;Creatinine Clearance Measurement;Dna Damage;Dna Injury;Development;Diagnosis;Diameter;Distant;Drug Formulations;Drug Kinetics;Ecsf;Economics;Encapsulated;Endogenous Nitrate Vasodilator;Endothelium-Derived Nitric Oxide;Epoetin;Equilibrium;Erythropoietin;Excision;Exhibits;Extirpation;Ferrimyoglobin;Formulation;Generalized Growth;Generations;Goals;Growth;Hif 1;Hif-1 Protein;Hif1;Hif1 Protein;Head Cancer;Head And Neck Cancer;Health Care Systems;Healthcare Systems;Hemoglobin;Human;Hyperbaric Oxygen;Hypertension;Hypoxia;Hypoxic;Image;In Situ;Infusion;Infusion Procedures;Injection Of Therapeutic Agent;Injections;Investigators;Jobs;Kinetics;Loinc Axis 2 Property;Loinc Axis 4 System;Laboratories;Lead;Mgc9013;Malignant Cell;Malignant Head And Neck Neoplasm;Malignant Neck Neoplasm;Malignant Neoplasms;Malignant Tumor;Malignant Tumor Of The Lung;Malignant Neoplasm Of Lung;Man (Taxonomy);Measures;Mediating;Metmyoglobin;Mice;Mice Mammals;Microcirculation;Modern Man;Molecular;Molecular Interaction;Monitor;Mononitrogen Monoxide;Murine;Mus;Myoglobin;Myoglobinuria;Nsclc;Nsclc - Non-Small Cell Lung Cancer;Nanoscale Science;Nanotechnology;Neck Cancer;Nitric Oxide;Nitrogen Monoxide;Nitrogen Protoxide;Non-Small Cell Lung Cancer;Non-Small-Cell Lung Carcinoma;O Element;O2 Element;Occupations;Operative Procedures;Operative Surgical Procedures;Oxygen;Oxygen Deficiency;Oxygen Measurement, Partial Pressure, Arterial;Particle Size;Patients;Pb Element;Pharmacodynamics;Pharmacokinetics;Phase;Polymers;Production;Professional Postions;Property;Proteins;Public Health;Pulmonary Cancer;Pulmonary Malignant Neoplasm;Radiation;Radiation Oncology;Radiation Sensitizers;Radiation Therapy;Radiation-Sensitizing Agents;Radiation-Sensitizing Drugs;Radiosensitizing Agents;Radiosensitizing Drugs;Radiotherapeutics;Radiotherapy;Removal;Reporter;Research;Research Personnel;Researchers;Resistance;Rhabdomyolysis;Sbir;Sbirs (R43/44);Site;Small Business Innovation Research;Small Business Innovation Research Grant;Solid Neoplasm;Solid Tumor;Solutions;Staging;Stimulus;Structure;Surgical;Surgical Interventions;Surgical Procedure;Surgical Removal;Suspension Substance;Suspensions;System;Tnfrsf5;Tnfrsf5 Gene;Tail;Testing;Therapeutic;Time;Tissue Growth;Tissues;Toxic Effect;Toxicities;Treatment Failure;Tumor Necrosis Factor Receptor Superfamily Member 5 Gene;Tumor Oxygenation;United States;Universities;Vascular Hypertensive Disease;Vascular Hypertensive Disorder;Vascular Constriction (Function);Vasoconstriction;Veins;Vesicle;Viscosity;Weight;Work;Animal Data;Arterial Po2;Balance;Balance Function;Base;Bionano Technology;Bionanotechnology;Cancer Cell;Cancer Diagnosis;Chemical Stability;Chemotherapy;Clinical Hyperthermia;Cost;Developmental;Endothelial Cell Derived Relaxing Factor;Erythrocyte Colony Stimulating Factor;Gene Product;Heavy Metal Pb;Heavy Metal Lead;Hematopoietin;High Blood Pressure;Hyperpiesia;Hyperpiesis;Hypertensive Disease;Hyperthermia Treatment;Hypoxia Inducible Factor 1;Imaging;Immunogenicity;Improved;In Vivo;Lung Cancer;Malignancy;Malignant Head And Neck Tumor;Malignant Neck Tumor;Meetings;Met-Myoglobins;Nano Biotechnology;Nano Meter Scale;Nano Meter Sized;Nano Particle;Nano Scale;Nano Scale Science;Nano Tech;Nano Technology;Nanobiotechnology;Nanometer Scale;Nanometer Sized;Nanoparticle;Nanoscale;Nanotech;Neoplasm/Cancer;Nephrotoxicity;Nonsmall Cell Lung Cancer;Novel;Ontogeny;Oxygen Tension;P50;Particle;Pre-Clinical;Preclinical;Prevent;Preventing;Professor;Public Health Medicine (Field);Radiosensitizer;Ray (Radiation);Resection;Resistant;Response;Standard Of Care;Success;Surgery;Suspension;Tumor;Uptake
